Clinical Trials

The University of Virginia Cancer Center frequently opens new clinical trials, offering your patients the latest investigational treatments. For a complete list of active trials and study coordinator contact information, visit our newly launched Find a Clinical Trial website.

If you have patients who may be eligible to participate in a clinical trial, please email




New Trials Available at UVA

Metastatic Triple-Negative Breast Cancer (IRB-HSR #19307)

Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer (NCT02657889)

Primary Investigator: Patrick Dillon
Clinical Research Coordinator: Natalie Salsini



Prostate Cancer (IRB-HSR #19583)

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer  (NCT02799602)

Primary Investigator: Robert Dreicer
Clinical Research Coordinator: Cody Slicker

Metastatic Urothelial Carcinoma (IRB-HSR #19436)

A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma (NCT02567409)

Primary Investigator: Robert Dreicer
Clinical Research Coordinator: Julio Torres

Ovarian Cancer (IRB-HSR #19128)

A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer (NCT02718417)

Primary Investigator: Linda Duska
Clinical Research Coordinator: Heather Lothamer

Advanced Malignancies (IRB-HSR #18488)

A Pilot Study to Assess the Combination of High-Dose Conformal Radiation Therapy (HDCRT) and Pembrolizumab in Modulating Local and Systemic T-cell Responses in Advanced Malignancies

Primary Investigator: James Larner
Clinical Research Coordinator: Emily Allred, Sarah Kelley

Metastatic Solid Tumors (IRB-HSR #19390)

First In-Human, Dose-Escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate (Humax®-TF-ADC) In Patients with Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor (NCT02001623)

Primary Investigator: Robert Dreicer
Clinical Research Coordinator: Cody Slicker